^
Association details:
| Biomarker: | PIK3CA mutation + ER positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | everolimus (mTOR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer
Published date:
08/14/2020
Excerpt:
However, the switch to either alpelisib or everolimus monotherapy induced complete tumor growth inhibition for over 6 weeks of treatment in both models (Fig. 3a, b).
DOI:
10.1186/s13058-020-01320-8
